A kind of decellularized aortic valve stent and its preparation method and application
An aortic valve and decellularization technology, applied in the field of medical materials, can solve the problems of loss of surface components, difficult extracellular matrix integrity and mechanical properties, unsatisfactory decellularization effect, etc., to achieve good biocompatibility and mechanical properties performance, good biodegradability and compatibility, non-antigenic and immunogenic effects
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
preparation example Construction
[0065] The present invention simultaneously provides a kind of preparation method of aortic valve stent, and it comprises the following steps:
[0066] (1) placing the animal aortic valve in a buffer solution containing polyethylene glycol-polycaprolactone;
[0067] as well as
[0068] (2) The aortic valve is placed in a nuclease-containing buffer solution for treatment.
Embodiment 1
[0104] 1. Solution preparation
[0105] (1) Hypertonic TRIS buffer solution (0.05mol / L): Accurately weigh 0.6057g of TRIS (MW121.14) and add a certain amount of triple-distilled water, adjust the pH to 8.0 with hydrochloric acid, and adjust the volume to 100ml with triple-distilled water. Prepared buffers are autoclaved.
[0106] (2) Hypotonic TRIS buffer (0.01mol / L): Dilute the prepared hypertonic TRIS buffer (0.05mol / L) 5 times with triple distilled water to obtain hypotonic TRIS buffer (0.01mol / L), The prepared buffer solution is autoclaved.
[0107] (3) 1% (w / v) PEG-PCL decellularization solution: Weigh 1g PEG-PCL, dissolve it in 100ml hypotonic TRIS buffer (0.01mol / L), fully dissolve to obtain 1% (w / v ) PEG-PCL decellularized solution.
[0108] 2. Synthesis and characterization of polyethylene glycol-polycaprolactone (PEG-PCL)
[0109] 2.1 Synthesis of polyethylene glycol-polycaprolactone (PEG-PCL)
[0110] The hydrophilic PEG-PCL used in this embodiment is self-synt...
Embodiment 2
[0199] Figure 7 with Figure 8 is the accompanying drawing of embodiment two, wherein Figure 7 It is the HE staining figure of the valve described in embodiment two; Figure 8 It is the MASSON staining figure of the valve described in Example 2.
[0200] The difference between embodiment two and embodiment one is:
[0201] 1. The solution is prepared as follows:
[0202] (1) Hypertonic TRIS buffer solution (0.08mol / L): Accurately weigh 0.9691g of TRIS (MW121.14) and add a certain amount of triple-distilled water, adjust the pH to 8.0 with hydrochloric acid, and adjust the volume to 100ml with triple-distilled water. Prepared buffers are autoclaved.
[0203] (2) Hypotonic TRIS buffer (0.02mol / L): Dilute the prepared hypertonic TRIS buffer (0.08mol / L) 4 times with triple distilled water to obtain hypotonic TRIS buffer (0.02mol / L), The prepared buffer solution is autoclaved.
[0204] (3) 2% PEG-PCL decellularization solution: Weigh 2g PEG-PCL, dissolve in 100ml hypotonic...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More